CSPC Pharma has HKD 0.18 dividend with October 20 ex-date for CSPC Pharma stock

Published on 10/20/2026 at 20:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SYS6088 wins approval October 15, 2026. CSPC Pharma stock costs EUR 1.02 on October 20, 2026.

Dividend and pipeline facts

CSPC Pharma has an HKD 0.18 cash dividend with an October 20, 2026 ex-dividend date.
SYS6088 received clinical trial approval in China on October 15, 2026.
CSPC Pharma stock was trading at EUR 1.02 at Lang & Schwarz on October 20, 2026 at 8:18 p.m. CEST.
Reported first-half 2026 revenue reached RMB 18,594 million, while reported profit rose to RMB 6,094 million.

CSPC Pharma, HK1093012172, Illustration mit AI erstellt.

CSPC Pharma (ISIN HK1093012172) has an HKD 0.18 cash dividend with an ex-dividend date of October 20, 2026, according to Yahoo Finance. The stock was trading at EUR 1.02 at Lang & Schwarz on October 20, 2026 at 8:18 p.m. CEST.

China trial pipeline expands

CSPC Pharmaceutical Group said SYS6088 injection, a tri-specific antibody, obtained clinical trial approval in China on October 15, 2026. The company also listed the approval among its latest investor-relations updates, placing the pipeline alongside the dividend date as a current shareholder reference.

On October 15, 2026, the company also reported a clinical trial approval for SYS6062 injection in China, according to CSPC Pharmaceutical Group. The two approvals point to continued investment in oncology and biologic medicines, although the releases do not quantify potential sales.

Revenue growth remains substantial

For the first half of 2026, revenue reached RMB 18,594 million, up 40.1 percent from the prior-year period. Reported profit attributable to shareholders rose 139.2 percent to RMB 6,094 million, while underlying profit increased 165.8 percent to RMB 6,164 million, according to CSPC Pharmaceutical Group.

Peer valuation stays mixed

At the Hong Kong close on October 20, 2026, CSPC Pharma stood at HKD 8.92, with a price-to-earnings ratio of 11.68 and a market capitalization of HKD 101.7 billion. Sino Biopharmaceutical stood at HKD 5.40, up 2.86 percent, with a price-to-earnings ratio of 34.75 and a market capitalization of HKD 96.1 billion. Jiangsu Hengrui Medicine stood at CNY 47.45, up 2.97 percent, with a price-to-earnings ratio of 40.56 and a market capitalization of CNY 302.7 billion.

Dividend date and market view

The October 20 ex-dividend date gives the shareholder calendar a concrete near-term marker. The interim results provide the operating counterpoint: reported profit of RMB 6,094 million was 139.2 percent higher than in the first half of 2025, while underlying profit rose 165.8 percent.

Stock price and investor context

The euro quotation puts the German investor view at EUR 1.02 at Lang & Schwarz on October 20, 2026 at 8:18 p.m. CEST. The Hong Kong listing had closed at HKD 8.92 at 4:08 p.m. HKT on the same date.

The further course of trading is shown by the continuously updated real-time quote of CSPC Pharma stock.